Key Documents

View All Documentation

Perphenazine

Name: Perphenazine
Brand: SIGMA

Synonym(s):

4-[3-(2-Chloro-10H-phenothiazin-10-yl)propyl]-1-piperazineethanol

Select a Size

Change View

Pack Size	SKU	Availability	Price

About This Item

Empirical Formula (Hill Notation):

C₂₁H₂₆ClN₃OS

CAS Number:

58-39-9

Molecular Weight:

403.97

NACRES:

NA.77

PubChem Substance ID:

24278642

UNSPSC Code:

12352200

EC Number:

200-381-5

MDL number:

MFCD00056798

Form:

powder

Quality level:

200

Pricing and availability is not currently available.

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

form

powder

Quality Level

200

originator

Schering Plough

storage temp.

2-8°C

SMILES string

ClC(C=C1)=CC2=C1SC3=CC=CC=C3N2CCCN4CCN(CCO)CC4

InChI

1S/C21H26ClN3OS/c22-17-6-7-21-19(16-17)25(18-4-1-2-5-20(18)27-21)9-3-8-23-10-12-24(13-11-23)14-15-26/h1-2,4-7,16,26H,3,8-15H2

InChI key

RGCVKNLCSQQDEP-UHFFFAOYSA-N

Gene Information

human ... ADRA1A(148), ADRA1B(147), ADRA1D(146), ADRA2A(150), ADRA2B(151), ADRA2C(152), DRD2(1813), OPRS1(10280)

Description

General description

Perphenazine is an antipsychotic drug used in treating schizophrenia. It modulates antioxidant levels and helps in the management of oxidative injury in schizophrenia. However, it is less effective than the clozapine drug group in improving response to oxidative injury.

Biochem/physiol Actions

D₂ dopamine receptor antagonist; α-adrenergic receptor antagonist and σ-receptor agonist; phenothiazine antipsychotic. Inhibits glutamate dehydrogenase in vitro.

Features and Benefits

This compound was developed by Schering Plough. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item	P0550000	BP422	1511000
Sigma-Aldrich P6402 Perphenazine	P0550000 Perphenazine	BP422 Perphenazine	USP 1511000 Perphenazine
form powder	form -	form solid	form -
Quality Level 200	Quality Level -	Quality Level -	Quality Level -
storage temp. 2-8°C	storage temp. 2-8°C	storage temp. 2-8°C	storage temp. -
originator Schering Plough	originator -	originator -	originator -
Gene Information human ... ADRA1A(148), ADRA1B(147), ADRA1D(146), ADRA2A(150), ADRA2B(151), ADRA2C(152), DRD2(1813), OPRS1(10280)	Gene Information human ... DRD2(1813)	Gene Information human ... DRD2(1813)	Gene Information human ... DRD2(1813)

Still not finding the right product?

Explore all of our products under Perphenazine

pictograms

GHS07

signalword

Warning

hcodes

H302,H317

pcodes

P261 - P264 - P272 - P280 - P301 + P312 - P302 + P352

Hazard Classifications

Acute Tox. 4 Oral - Skin Sens. 1

Storage Class

11 - Combustible Solids

wgk

WGK 3

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Choice of randomization to clozapine versus other second generation antipsychotics in the CATIE schizophrenia trial.

Eric Hermes et al.

Journal of psychopharmacology (Oxford, England), 26(9), 1194-1200 (2012-04-21)

There is evidence to suggest that clozapine is underutilized in treatment-refractory schizophrenia. Data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), a multi-phase, randomized comparative effectiveness trial for schizophrenia, were used to identify factors associated with choosing randomization to

Fast-dissolving sublingual solid dispersion and cyclodextrin complex increase the absorption of perphenazine in rabbits.

Elina Turunen et al.

The Journal of pharmacy and pharmacology, 63(1), 19-25 (2010-12-16)

The sublingual administration route as well as solid dispersion formation with macrogol 8000 and complexation with β-cyclodextrin (β-CyD) were investigated as ways for improving the absorption of perphenazine, a poorly water-soluble drug subjected to substantial first-pass metabolism. The absorption of

Impact of the CATIE trial on antipsychotic prescribing patterns at a state psychiatric facility.

Angela M Koranek et al.

Schizophrenia research, 137(1-3), 137-140 (2012-03-01)

Results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) indicate that, with the exception of olanzapine, no substantial overall differences were identified between second generation antipsychotics (SGAs) and the first generation antipsychotic (FGA) perphenazine. This study evaluated the effect

View All Related Papers

Global Trade Item Number

SKU	GTIN
P6402-5G	04061832092775
P6402-1G	04061834393320